Business Wire

SIMPLYBOOK.ME

Share
SimplyBook.me Ltd. - Turning a Global Challenge into an Opportunity

The SimplyBook.me appointment scheduling system, originally created as a solution for a popular tire workshop in Iceland, is now processing millions of Covid vaccination and Covid test bookings worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005729/en/

Early 2020, when the pandemic started to spread, the management and staff of SimplyBook.me worried how it might affect the company and its future with the core clients being smaller service businesses. The management team took the stand to use the company's reserve funds to keep all its qualified staff, even though the situation might drag on for months. At the same time, work began to evaluate if SimplyBook.me could find its place in the fight against the spread of the virus.

At this point, widespread Covid testing had not begun, and social distancing and masks were the order of the day. The team immediately identified opportunities to help with organising social distancing as well as Covid testing. Despite the bombardment of cancellation requests from smaller service businesses using the software that experienced lockdowns and inability to function, the COVID-related services continued to grow stronger.

NHS in the UK approached SimplyBook.me during the summer of 2020 as they needed a booking solution to help them organise Covid testing in one of their areas. We jumped on the opportunity and fine-tuned our software to customise to their needs. The results spoke for themselves, and more and more NHS trusts joined up to use the software. When it became apparent that the UK was going to be the first to start vaccinating, SimplyBook.me put the full force of their development and support teams on setting up the software so it would work for vaccinations in the best way possible.

"The project leader and team we've been working with at the NHS, are outstanding in their work and organisation. I sincerely hope the UK administration understands the quality of all the people working behind the scenes so that everything works as planned. They are incredibly professional and demand nothing less than perfection" said Ingvar Gudmundsson founder and VP-Sales at SimplyBook.me. "It is a privilege to work with such dedicated people who are doing their utmost to deliver the best."

"It is now early 2021, and we are proud to have taken a direct part in the fight against the virus throughout the past ten months. The cherry on the top is knowing that we are now being used for vaccination scheduling, processing millions of bookings in only the first few weeks since it started. We were always confident that we had built a great flexible software, adaptable to be used in all sorts of situations. This original vision has helped us grow faster than ever, keep all staff fully employed, and finally be at the forefront in the fight against the biggest plague of the last century."

________________________________________________________________________

SimplyBook.me is one of the world's top booking systems – a 360-degree software service which acts as a growth tool for SMEs, health organisations and educational institutions. The SimplyBook.me mission is bringing people and service businesses together by enabling them to easily book their services online no matter where, when or which.

Link:

ClickThru

Social Media:

https://www.facebook.com/simplybook

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release

Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release

Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye